First Hospital of Kunming

Kunming, China

First Hospital of Kunming

Kunming, China
Time filter
Source Type

Jiao K.,Gansu Provincial Hospital | Qin J.,First Hospital of Kunming | Zhao Y.,Gansu Provincial Hospital | Zhang H.,First Hospital of Kunming
NeuroReport | Year: 2016

Ligase IV and XRCC4 genes, important molecules in the nonhomologous end-joining pathway for repairing DNA double-strand breaks, may play crucial roles in carcinogenesis. To detect their effects on the risk of human glioma, their gene expression differences between 110 human glioma tissues and 50 healthy brain tissues were determined using quantitative real-time PCR. Furthermore, two tagging single nucleotide polymorphisms (SNPs) in ligase IV and four SNPs in XRCC4 genes were genotyped in 317 glioma patients and 352 healthy controls. The association of glioma and ligase IV/XRCC4 was evaluated using methods for SNP, haplotype, and gene-gene interaction analysis. Compared with those in normal brain tissues, the relative gene expression levels of ligase IV and XRCC4 were significantly downregulated in glioma tissue (P=0.0017 and 0.0006, respectively). Single SNP analysis indicated that only rs10131 in ligase IV remained significantly associated with glioma (P=0.0036) after 10 000 permutation tests. Haplotype analysis showed that the haplotype profiles of ligase IV and XRCC4 were significantly different between glioma patients and healthy controls (P=0.004 and 3.13E-6, respectively). Finally, the gene-gene interaction analysis suggested that the three-locus model (rs1805388, rs10131, and rs2075685) was the best model for ligase IV and XRCC4 to have interaction effects on the risk of glioma. In conclusion, both ligase IV and XRCC4 may act in concert to modulate the development of glioma. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.

Li L.,First Hospital of Kunming | Li C.,Dali University | Zhong H.,Kunming Medical University | Tao Y.,Kunming Medical University | And 2 more authors.
PLoS ONE | Year: 2016

Purpose We aim to assess the longitudinal association between baseline estimated cerebrospinal fluid pressure (CSFP) and 5-year incident primaryopen angle glaucoma (POAG) in a population- based sample of Bai Chinese living in rural China. Methods Among the 2133 Bai Chinese aged 50 years or older who had participated in the baseline examination of the Yunnan Minority Eye Study, 1520 (71.3%) attended the follow-up examination after five years and 1485 were at risk of developing POAG. Participants underwent comprehensive ophthalmic examinations at both baseline and follow-up surveys. CSFP in mmHg was estimated as 0.55 × body mass index (kg/m2) + 0.16 × diastolic blood pressure (mmHg)-0.18 × age (years)-1.91. Glaucoma was defined using the International Society of Geographical and Epidemiological Ophthalmology Classification criteria. Multivariate logistic regression models were established to determine the association between baseline CSFP and incident POAG. Results After a mean follow-up time of 5 years, 19 new cases of POAG were detected, with an incidence rate of 1.3% (95% confidence interval, 0.7-1.9%). Inmultivariate logistic regression analysis, after adjusting for age, gender, education, intraocular pressure, central corneal thickness, hypertension and diabetes, no significant associations, nor any trends, were evident between baseline estimated CSFP and incident POAG. The association between estimated CSFP per mmHg increase in baseline and 5-year incidence of POAG was also nonsignificant, with adjusted relative risk of 0.96 (P = 0.11) in multivariate analysis. Conclusions This longitudinal cohort study does not support previously observed cross-sectional association between estimated CSFP and POAG in population-based studies. © 2016 Li et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Shen H.,First Affiliated Hospital | Shen H.,Zhejiang University | Shen H.,First Hospital of Kunming | Lv Y.,First Affiliated Hospital | And 17 more authors.
Plastic and Reconstructive Surgery | Year: 2012

Background: Polyacrylamide hydrogel has been used for soft-tissue augmentation for more than 10 years. Although it is considered a nontoxic, nonimmunogenic material, complications after polyacrylamide hydrogel injections during facial soft-tissue augmentation have been reported. Methods: Between 2003 and 2009, 24 patients underwent surgical management of complications after facial soft-tissue augmentation. Histories, preoperative imaging, and photographs of operations were recorded. Results: Complications included hematomas, infection, nodule formation, and migration. Ultimately, 23 of 24 cases underwent surgery to remove the gel; the remaining case underwent surgical drainage to remove it. Conclusions: As more complications have been reported, especially ones that are difficult to treat, the safety of polyacrylamide hydrogel needs to be reconsidered. The authors' experiences provide methods to remove polyacrylamide hydrogel if complications occur. Clinical Question/Level of Evidence: Therapeutic, V. Copyright © 2012 by the American Society of Plastic Surgeons.

Hu J.,Central South University | Hu J.,First Hospital of Kunming | Lv G.,Central South University | Zhou S.,Central South University | And 7 more authors.
PLoS ONE | Year: 2015

Background: Osteosarcoma is the most common primary bone malignancy in children and young adults. Increasing results suggest that discovery of microRNAs (miRNAs) might provide a novel therapeutical target for osteosarcoma. Methods: MiR-182 expression level in osteosarcoma cell lines and tissues were assayed by qRT-PCR. MiRNA mimics or inhibitor were transfected for up-regulation or down-regulation of miR-182 expression. Cell function was assayed by CCK8, migration assay and invasion assay. The target genes of miR-182 were predicated by bioinformatics algorithm (TargetScan Human). Results: MiR-182 was down-regulated in osteosarcoma tissues and cell lines. Overexpression of miR-182 inhibited tumor growth, migration and invasion. Subsequent investigation revealed that TIAM1 was a direct and functional target of miR-182 in osteosarcoma cells. Overexpression of miR-182 impaired TIAM1-induced inhibition of proliferation and invasion in osteosarcoma cells. Conclusions: Down-expression of miR-182 in osteosarcoma promoted tumor growth, migration and invasion by targeting TIAM1. MiR-182 might act as a tumor suppressor gene whose downregulation contributes to the progression and metastasis of osteosarcoma, providing a potential therapy target for osteosarcoma patients. © 2015 Hu et al.

Cao Q.,First Hospital of Kunming | Li L.,First Hospital of Kunming | Li Y.-C.,First Hospital of Kunming | Dai H.-M.,First Hospital of Kunming | And 2 more authors.
Zhonghua Shiyan Yanke Zazhi/Chinese Journal of Experimental Ophthalmology | Year: 2012

Background: Prevention and treatment of posterior capsular opacification (PCO) is a hot issue. To establish a PCO animal model is the basis of relevant studies. The most common methods of creating a PCO model are phacoemulsification surgery with or without intraocular lens (IOL) implantation. But the suitability of different methods is unclear. Objective: This experiment was to compare the outcome between the two methods of establishing a PCO model in rabbit eyes. Methods: Twenty New Zealand white rabbits were collected and randomized into 2 groups. Phacoemulsification of cataract with IOL or without IOL implantation was performed on the right eyes of rabbits in these two groups. The operative eyes were examined under the slit lamp from day 1 through 3 months after surgery. The inflammatory response was evaluated and compared between the two groups, and the extent of PCO was graded based on Odrich's criteria. The use of the animals complied with the Regulations for the Administration of Affairs Concerning Experimental Animals by State Science and Technology Commission. Results: The inflammatory response, including conjunctival congestion, corneal edema and aqueous flare were less severe in the model eyes with IOL implantation than the eyes without IOL implantation 1-3 days after operation. Inflammatory response gradually disappeared and showed the same degree in the PCO grade from 2 weeks through 3 months in both groups. The numbers of eyes with 1-3 grade of PCO were 8 and 9, and those with 0 grade of PCO were 2 and 1 in the with IOL implantation group and without IOL implantation group, respectively, showing a significant difference (P = 0.39). PCO appeared at 1 month, extended at 2 months and formed dense fibrosis following operation. Conclusions: The model outcome of phacoemulsification combined with IOL implantation is better than without IOL implantation one. It is the ideal animal model for the study of after cataract. Copyright © 2012 by the Chinese Medical Association.

Su X.,First Hospital of Kunming | Zhang L.,First Hospital of Kunming | Jin L.,First Hospital of Kunming | Ye J.,First Hospital of Kunming | And 2 more authors.
Journal of Clinical Immunology | Year: 2010

Introduction: Dendritic cells (DCs) have greater stimulating activity on innate and adaptive immunity following short-term sensitization with zoledronate acid (DCsZol). We identified the phenotype, cytotoxicity, and mechanisms of killing of cytokine-induced killer (CIK) cells which were cocultured with DCsZol. Methods: Adherent and nonadherent cells of peripheral blood mononuclear cell from myeloma patients were incubated for DCs and CIK cells. Then, the CIK cells were cocultured with DCsZol (DCsZol-CIK). Expression of markers for DCsZol-CIK cells was measured using flow cytometry. Cytotoxicity was evaluated by against human myeloma cell lines and mechanisms of killing were tested by selectively blocking NKG2D receptor. The anti-tumor activity of these effector cells was further evaluated using a nude mice tumor model. Results: γδ TCR expression of CIK cells significantly increased after coculture with immature or mature DCsZol (iDCs/mDCsZol-CIK) and these cells aggressively lysed myeloma cells compared with mDCs-CIK and zoledronate acid pulsed CIK cells (CIKZol; 50.8 ± 7.9% and 48.2 ± 4.7% versus 31.9 ± 5.1% and 20.5 ± 3.6%, effector versus target ratio was 60:1). Both αβ T and γδ T cells in the iDCsZol-CIK cells performed the majority of lysis. The iDCs/mDCsZol-CIK cells greatly increased NKG2D expression compared with mDCs-CIK and CIKZol during culture (71.5 ± 11.3% and 67.7 ± 9.3% versus 51.3 ± 6.2% and 47.1 ± 5.7%). iDCsZol-CIK cell-mediated lysis dropped 69.21% when the NKG2D receptor was blocked and the cytotoxicity correlated with NKG2D ligand-MICA expression on the target cells. In a human myeloma bearing nude mice model, iDCsZol-CIK and mDCsZol-CIK cells treatment groups obtained 75% and 62.5% long-term survival (>120 days) respectively, as compared with none of the control animals or 37.5% treated with mDCs-CIK cells. Conclusion: Large numbers of CIK cells with greater anti-tumor activities are rapidly generated by Zol-treated iDCs/mDCs. This strategy is worthy of further investigation to improve adoptive cell therapy against tumors. © 2010 Springer Science+Business Media, LLC.

Su X.,First Hospital of Kunming | Zhang L.,First Hospital of Kunming | Wu S.,First Hospital of Kunming | Jin L.,First Hospital of Kunming | And 3 more authors.
Cancer Biotherapy and Radiopharmaceuticals | Year: 2011

Adoptive tumor-infiltrating lymphocytes (TILs) therapy has demonstrated drastic effects on advanced malignant melanoma. Intensive pretreatment such as chemotherapy and/or total body irradiation has been used to eliminate immunosuppressive components and therefore enhances the antitumor effects of TILs. However, these pretreatments may cause severe side effects, especially for elderly patients. This case observes the complete response of how a patient with metastatic melanoma was treated sequentially with local tumor resection, postoperative adoptive cytokine-induced killer cells and TILs infusion. In addition, the cascading adoptive cell therapy was well-tolerated by the patient. Therefore, being pretreated with cytokine-induced killer cells could ameliorate the immunosuppressive condition in the patient and provide a favorable circumstance for subsequent TILs infusion. The further adoptive TILs therapy could exert the most powerful antitumor activity in such an amicable circumstance. © 2011, Mary Ann Liebert, Inc.

Chen X.,Kunming Medical University | Liu Z.,Kunming Medical University | Huang Y.,Kunming Medical University | Li R.,Kunming Medical University | And 8 more authors.
Autoimmunity | Year: 2014

Background: The development of protocols for the ex vivo generation of dendritic cells (DCs) has led to intensive research into their potential use in immunotherapy in the treatment of cancer. In this study, we examined the efficacy of dendritic cell-tumor cell fusion hybrid vaccines in eliciting an immune response against Lewis lung carcinoma (LLC) cells, as compared to other types of tumor vaccines. In addition, we also tested whether the efficacy of the vaccines was affected by the route of administration. Four different tumor vaccines were compared: (1) HC (hybrid cell), consisting of DC/LLC hybrids; (2) DC+LLC (DCs pulsed with apoptotic LLCs); (3) DC without antigen loading/pulsing; (4) LLC (apoptotic/irradiated tumor cells). We also compared four different routes of administration for each vaccine: (1) Preimmunization; (2) Vaccination therapy; (3) Adoptive immunotherapy; (4) Vaccination therapy combined with adoptive immunotherapy. Anti-tumor immunity was assessed in vivo and the CTL (cytotoxic T lymphocyte) response as well as the expression of key cytokines, IFN-γ and IL-10 were further evaluated using in vitro assays. Results: Our data demonstrate that vaccination with HC hybrids provides more effective anti-tumor protective immunity and significantly greater therapeutic immunity than vaccination with DC+LLC, DC or LLC. Most remarkably, vaccination therapy with HC hybrids was more successful than combination (vaccination+adoptive) therapy for the induction of anti-tumor responses. Splenocytes harvested from mice immunized with HC hybrids demonstrated the greatest cytotoxic T lymphocyte (CTL) activity and their production of IFN-γ was high, while their production of IL-10 was very low. Conclusions: Our results suggest that vaccination therapy with DC-tumor cell fusion hybrids provides more effective protection against lung cancer. © 2014 Informa UK Ltd.

Su X.,First Hospital of Kunming | Zhang L.,First Hospital of Kunming | Jin L.,First Hospital of Kunming | Ye J.,First Hospital of Kunming | And 3 more authors.
Cancer Biotherapy and Radiopharmaceuticals | Year: 2010

Cytokine-induced killer (CIK) cells have shown antitumor activity against several tumor cells both in vitro and in vivo. This study reports on the large-scale expansion of CIK cells and also present preliminary results from a pilot clinical trial. Sixteen (16) patients with renal cell carcinoma (RCC), all of whom had metastases after radical nephrectomy and adjuvant therapy using interferon-α (IFN-α) and/or interleukin-2 (IL-2), were treated with CIK cells. CIK cells were generated from peripheral blood mononuclear cells (PBMCs) and incubated in the presence of IFN-γ followed by OKT3 and IL-2. Treatment schedule consisted of two to three cycles of CIK cell infusions at an interval of 3 weeks. A total of 46 infusions were administered to 16 metastatic RCC (mRCC) patients. The median number of transferred cells per treatment was 6.7 × 109 (range, 2.5-12.3). At a 60:1 effector-target cell ratio, CIK cells killed 51.4% and 32.1% of two human kidney tumor cell lines (293 and SK-RC-42), respectively. After CIK cell infusion, the percentage of CD3+, CD8+, CD3+CD56+, and NKG2D+ cells and the intracellular products of two type 1 cytokines (IFN-γ and tumor necrosis factor α) significantly increased in the patients' PBMCs. Toxicity was minimal, and there were no immediate adverse reactions to the infusions. Three (3) patients had complete response, 1 patient had partial response, and 6 patients had stable disease. These results showed that adoptive CIK cell immunotherapy is a safe and effective treatment, which may have essential benefits for the improvement of the immunologic function in mRCC patients and play an important role in the treatment of mRCC. © 2010, Mary Ann Liebert, Inc.

Loading First Hospital of Kunming collaborators
Loading First Hospital of Kunming collaborators